LRPAP1 Antibody targets the LRPAP1 protein, a chaperone involved in LDL receptor-related protein (LRP1) trafficking and implicated in autoimmune diseases and cancers like mantle cell lymphoma (MCL) . FITC conjugation (fluorescein isothiocyanate) enables fluorescent detection of LRPAP1 in cellular assays.
Therapeutic Targeting:
Bispecific constructs (e.g., anti-CD3/LRPAP1) and IgG1-format BAR bodies use LRPAP1 to redirect T/NK cells against MCL cells . FITC-labeled antibodies could track these constructs’ binding efficiency.
Viral Immune Evasion:
LRPAP1 binds IFNAR1 (interferon receptor), promoting its degradation and enhancing viral replication (e.g., EV71, HCoV-OC43) . FITC-conjugated antibodies confirmed extracellular LRPAP1’s role in IFNAR1 downregulation .
Prognostic Value:
LRPAP1 autoantibodies (IgG/IgM) in MCL patients correlate with superior survival (5-year OS: 93% vs. 68% in seronegative patients) .
Sensitivity: FITC conjugation requires optimization to avoid photobleaching during fluorescence assays .
Cross-Reactivity: Validated in human, mouse, and rat models, but species-specific validation is recommended .
Storage: Stable at -20°C; avoid repeated freeze-thaw cycles .